HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

eicosapentaenoic acid ethyl ester

Also Known As:
5,8,11,14,17-eicosapentaenoic acid, ethyl ester, (5Z,8Z,11Z,14Z,17Z)-; AMR-101; AMR101; Epadel; ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate; ethyl all-cis-5,8,11,14,17-icosapentaenoate; ethyl eicosapentaenoate; ethyl eicosapentaenoic acid; ethyl icosapentaenoate; ethyl-EPA; ethyl-eicosapentaenoic acid; icosapent ethyl; vascepa
Networked: 240 relevant articles (37 outcomes, 96 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Ballantyne, Christie M: 23 articles (01/2022 - 02/2013)
2. Bhatt, Deepak L: 22 articles (01/2022 - 01/2019)
3. Juliano, Rebecca A: 18 articles (01/2022 - 05/2015)
4. Doyle, Ralph T: 16 articles (01/2022 - 05/2015)
5. Granowitz, Craig: 15 articles (01/2022 - 01/2019)
6. Brinton, Eliot A: 13 articles (01/2022 - 07/2013)
7. Jacobson, Terry A: 13 articles (01/2022 - 06/2012)
8. Miller, Michael: 13 articles (01/2022 - 01/2019)
9. Jiao, Lixia: 12 articles (01/2022 - 01/2019)
10. Tardif, Jean-Claude: 11 articles (01/2022 - 01/2019)

Related Diseases

1. Cardiovascular Diseases (Cardiovascular Disease)
2. Hypertriglyceridemia
3. Huntington Disease (Huntington's Disease)
4. Type 2 Diabetes Mellitus (MODY)
5. Heart Failure
01/01/2022 - "Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT."
10/03/2020 - "The studies reviewed include clinical trials on novel RNA interference-based lipid-lowering therapies AKCEA-APOCIII-LRx and vupanorsen (AKCEA-ANGPTL3-LRx); the EVAPORATE trial assessing the effects of icosapent ethyl on coronary plaque volume progression; the LoDoCo2 trial evaluating the efficacy of low-dose colchicine in cardiovascular disease risk reduction among patients with chronic coronary artery disease; as well as the EMPEROR-Reduced trial evaluating cardiovascular and renal outcomes with empagliflozin in patients with heart failure and reduced ejection fraction. "
01/01/2022 - "Assessed studies examine a remotely delivered hypertension and lipid program in 10,000 patients across a diverse healthcare network; a cluster-randomized trial of a village doctor-led intervention for hypertension control; empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); efficacy and safety of empagliflozin in hospitalized heart failure patients (EMPULSE); icosapent ethyl versus placebo in outpatients with coronavirus disease 2019 (PREPARE-IT 2); clinical safety, pharmacokinetics, and low-density lipoprotein cholesterol-lowering efficacy of MK-0161, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor; and effects of aspirin on dementia and cognitive impairment in the ASCEND trial. "
02/01/2021 - "This review critically discusses the multiple benefits for women of new pharmacological treatments, such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter type 2 inhibitors (SGLT2i), proprotein convertase subtilisin/kexin type 9 inhibitors, inclisiran, icosapent ethyl and bempedoic acid in preventing cardiovascular events, and treatments, such as angiotensin receptor neprilysin inhibitors, SGLT2i, vericiguat and omecamtiv mecarbil, for preventing heart failure."
12/01/2022 - "Included studies assessed the effects of aspirin and omega-3 fatty acid supplements on heart failure (ASCEND study); the impact of icosapent ethyl on ST-elevation MI incidence (REDUCE-IT); air temperature's effect on cardiovascular mortality (EXHAUSTION project); LVEF outcomes after troponin-guided neurohormonal blockade for the prevention of anthracycline toxicity; efficacy of routine stress testing after high-risk PCI (POST-PCI trial); influenza vaccine among patients with acute coronary syndromes (VIP-ACS trial); empagliflozin in patients with acute myocardial infarction (EMMY); effects of comprehensive imaging-based cardiovascular screening on death and cardiovascular events (DANCANVAS); safety of long-term evolocumab in patients with established atherosclerotic cardiovascular disease (FOURIER-OLE); and use of a cardiovascular polypill as a global strategy to improve secondary prevention (SECURE). "

Related Drugs and Biologics

1. Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
2. Eicosapentaenoic Acid
3. Omega-3 Fatty Acids (Omega 3 Fatty Acids)
4. Esters
5. eicosapentaenoic acid ethyl ester
6. Lipids
7. Triglycerides (Triacylglycerol)
8. LDL Cholesterol
9. empagliflozin
10. oxidized low density lipoprotein

Related Therapies and Procedures

1. Therapeutics
2. Secondary Prevention
3. Drug Therapy (Chemotherapy)
4. Aftercare (After-Treatment)